Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Policy In Biosimilars, “Breakthrough” And Social Media Under New Management

This article was originally published in The Pink Sheet Daily

Executive Summary

Office of Medical Policy’s leadership gets reshuffled following retirement of the long-time CDER denizen Rachel Sherman.

Advertisement

Related Content

Chief Scientist At US FDA Is Hinton As Borio Moves To White House
FDA Drug Policy Office Director Candidate Getting Four-Month Tryout
Former FDA Medical Policy Head Joins Greenleaf, Will Highlight FDA As “Resource”
FDA Mines Small Field Of Industry Candidates To Fill Executive Vacancies
FDA Searches Small Industry Candidate Pool To Fill Executive Vacancies
CDER Begins Search for New Regulatory Policy Chief
FDA Again Taps Compliance Director For Globalization Post
Large Simple Trials Need FDA Boost, IoM Report Says
FDA's Office of Medical Policy Grows Into A "Super Office"; DDMAC Gets A Promotion

Topics

Advertisement
UsernamePublicRestriction

Register

PS075178

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel